pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,202 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints784BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6091Rare Disease1460Cardiology1094Hematology1029Immunology1009Vaccines913Pulmonology
  • HHS pushes FDA to formalize public release of rejection letters to drug makers
    HHS announced it is preparing a new FDA regulation that would codify the agency's practice of publishing complete response letters (CRLs) that inform pharmaceutical companies of a drug's rejection.…
    Endpoints · 1mo agoCRLNeutral↗ source
  • ACA insurers seek median 14% premium hike for 2027 as enrollment falls
    Insurers filing with state regulators for 2027 ACA plans are asking for a median premium increase of 14%, according to an analysis of filings in 16 states and the District of Columbia. This would…
    STAT · 1mo agoRegulatoryNegative↗ source
← prev
page 46 of 89
next →
73
fda recalls47
fda medwatch38
fda press28
906
Psychiatry & CNS724
Ophthalmology421
Pain400
Endocrinology & Metabolism384
Infectious Disease359
  • Biohaven targets muscle-sparing obesity market to compete with Lilly's GLP-1 drugs
    Biohaven is positioning itself to address obesity by developing treatments that preserve lean muscle, a differentiator from existing GLP-1 therapies. The company sees an opportunity to act as a "s…
    Endpoints · 1mo agoNeutral↗ source
  • Mass General Brigham nurses begin largest strike in Massachusetts over pay and benefits
    Thousands of nurses at Brigham and Women’s Hospital walked off the job on Wednesday, marking the first strike at the Harvard‑affiliated facility and the largest nurses walkout in the state’s histor…
    STAT · 1mo agoNegative↗ source
  • Sanofi proposes to cease negative statements about CSL's flu vaccine amid EU probe
    Sanofi has offered to stop making disparaging comments about CSL's flu vaccine following an investigation launched by the European Commission. The offer comes two weeks after the Commission began p…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • RFK Jr. moves to compile list of Covid-19 vaccine injuries to streamline compensation claims
    Health secretary Robert F. Kennedy Jr. announced plans to create a list of injuries that would be presumed caused by Covid-19 vaccines. The list would allow individuals who suffer from those condi…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • Longevity entrepreneur Bryan Johnson reveals he has autoimmune gastritis, a hard-to-diagnose stomach disease
    Bryan Johnson, known for his longevity ventures, announced on X that he has been diagnosed with autoimmune gastritis. The condition is a chronic inflammatory disease where antibodies attack stomac…
    STAT · 1mo agoNeutral↗ source
  • Another big premium hike on the horizon
    FDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnerships
    Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday. One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to AstraZ…
    Endpoints · 1mo ago↗ source
  • Satellos gives early look at Duchenne pill in adults ahead of key data in children
    Satellos Bioscience is building its case for a Duchenne muscular dystrophy pill with data in adult patients ahead of a potentially pivotal readout in children later this year. The Canadian biotech’…
    Endpoints · 1mo ago↗ source
  • Opinion: STAT+: What’s the right role for AI in dementia care?
    Three tricky questions about using AI in dementia care.
    STAT · 1mo ago↗ source
  • Opinion: The AI licensure debate is missing the point of licensure
    “AI will reshape medicine. The physicians who answer for the outcome must lead the way it enters patient care," write Afnan R. Tariq and Ami Bhatt.
    STAT · 1mo ago↗ source
  • Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits
    The newly approved over-the-counter CGM offers a new approach to tackling childhood obesity but also raises a host of questions.
    STAT · 1mo ago↗ source
  • STAT+: Trump administration pursues more durable changes to science policy after setbacks in court
    The White House has proposed sweeping changes to the bedrock regulation undergirding all federal contracts, empowering the executive branch to direct research, terminate grants, and external scient…
    STAT · 1mo ago↗ source
  • Vertex's Crinetics deal points to big ambitions for cystic fibrosis leader
    Vertex Pharmaceuticals' $10 billion acquisition of an endocrinology startup represents the company’s clearest and boldest step toward the upper echelon of the biopharma industry. Long a biotech suc…
    Endpoints · 1mo ago↗ source
  • Tampa General kicks off legal fight over Lilly's 340B restrictions
    Tampa General Hospital sued Eli Lilly for halting its 340B discounts, kicking off a broader fight over whether pharmaceutical companies can condition drug discounts on new claims data requirements.…
    Endpoints · 1mo ago↗ source
  • Vera's IgAN approval kicks off competition with Otsuka
    Vera Therapeutics’ fusion protein atacicept got an accelerated approval on Tuesday for a chronic autoimmune disease that damages the kidneys. The drug will be marketed as Trutakna for immunoglobuli…
    Endpoints · 1mo ago↗ source
  • STAT+: FDA approves Vera Therapeutics kidney disease treatment
    The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.
    STAT · 1mo ago↗ source
  • STAT+: The crumbling employer-based health insurance system
    Today's D.C. Diagnosis newsletter covers maintaining diversity in drug trials and troubling trends in employer-based health insurance.
    STAT · 1mo ago↗ source
  • Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
    Compass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to comple…
    Endpoints · 1mo ago↗ source
  • Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
    The GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety profi…
    Endpoints · 1mo ago↗ source
  • STAT+: Compass says depression drug has long-lasting benefits
    Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: America’s employer health insurance is decaying
    STAT's Bob Herman examines the under-the-radar crisis brewing in employer-based health insurance.
    STAT · 1mo ago↗ source
  • Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first half
    Biopharma's M&A engine is revved up and shows no signs of cooling off. Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $12.6 ...
    Endpoints · 1mo ago↗ source
  • MeiraGTx strikes royalty deal; Fore's 2023 Series D continues
    Plus, news about Kalohexis, Teva and Agios: 👑 MeiraGTx makes royalty deal with Oberland Capital: The gene therapy maker will get an initial $135 million via a $10 million equity investment ...
    Endpoints · 1mo ago↗ source